Identifying risk factors and biomarkers for severe CIP in lung cancer patients– a retrospective case series study
A decreased FVC below 1.96 emerged as a predictive factor for Grades 3-4 CIP, highlighting the importance of monitoring FVC in patients receiving ICIs.
Authors
- Jianya Zhou (ORCID: https://orcid.org/0000-0001-8196-0166)
- Guixian Wu (ORCID: https://orcid.org/0000-0003-4339-2633)
- Yuncui Gan (ORCID: https://orcid.org/0000-0002-4657-9498)
- Nan Jiang (ORCID: https://orcid.org/0000-0001-9221-9568)
- Binggen Wu
- Jianying Zhou (ORCID: https://orcid.org/0000-0002-8924-935X)
- Jingjing Qu (ORCID: https://orcid.org/0000-0002-8079-4722)
- Ting Wang (ORCID: https://orcid.org/0000-0001-9248-4361)
- Jing Zheng (ORCID: https://orcid.org/0000-0001-7696-9991)
- Yuekang Li
- Jinpeng Liu (ORCID: https://orcid.org/0009-0008-4305-8305)
Institutions
- Wenzhou Medical University (CN)
- Zhejiang Taizhou Hospital (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Immunotherapy
- Published
- 2024-10-27
- DOI
- https://doi.org/10.1080/1750743x.2024.2429369
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28